Alumis Inc. Common Stock
ALMS
$29.27
+7.33%
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing novel allosteric Tyrosine Kinase 2 (TYK2) inhibitors for immune-mediated and neuroinflammatory diseases. Its lead candidates are envudeucitinib for psoriasis and systemic lupus erythematosus, and A-005, a CNS-penetrant inhibitor for neuroinflammatory conditions. The company is a pure-play TYK2 specialist, positioning itself as a potential disruptor in a competitive autoimmune and neurology landscape. The current investor narrative is dominated by the stock's dramatic appreciation, fueled by positive clinical trial updates and significant institutional buying, as evidenced by recent news of a major investor's $8 million purchase, but this has raised the stakes for upcoming late-stage data to justify the valuation.…
ALMS
Alumis Inc. Common Stock
$29.27
Related headlines
Investment Opinion: Should I buy ALMS Today?
Paragraph 1 — Rating & Thesis: The synthesized recommendation is Hold. The core thesis is that while Alumis possesses a promising pipeline with blockbuster potential, its current valuation at a 345x PS ratio fully prices in that success, leaving no margin of safety and creating an asymmetric risk/reward profile skewed to the downside in the near term. The unanimous 'Buy' ratings from 7 analysts reflect optimism on the science but do not mitigate the extreme valuation risk.
Paragraph 2 — Supporting Evidence: The Hold rating is supported by four key data points: 1) The astronomical 345x PS ratio implies perfection, 2) The company is burning cash at a rate of -$71.91M per quarter with no profits, 3) Despite a 258% 1-year gain, the stock has corrected -31.93% in one month, signaling exhaustion, and 4) Analyst revenue estimates of $840.35M for the coming year, if achieved, would still require massive commercial execution to justify the current $8.3B market cap. The stock is trading 66% of its 52-week range, suggesting it is in a consolidation phase after a parabolic move.
Paragraph 3 — Risks & Conditions: The two biggest risks are clinical trial failure and valuation collapse from its current extreme levels. This Hold would upgrade to a Buy only if the stock price corrects significantly further (e.g., below $15) to provide a better entry point with a margin of safety, or if upcoming clinical data is overwhelmingly positive and accompanied by a sustainable breakout above the 52-week high of $30.6. It would downgrade to a Sell if revenue growth fails to materialize as forecasted or if cash burn accelerates unexpectedly. The stock is unequivocally overvalued relative to any traditional fundamental metric, trading on speculative future potential alone.
Sign up to view all
ALMS 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The investment case is a classic high-risk, high-reward biotech binary bet, currently priced for near-perfect success. The recent 32% pullback from highs suggests the market is beginning to price in some risk, but the valuation remains extreme. The stance would upgrade to bullish only on a significant price correction (below $15) providing a better risk/reward entry, or unequivocally positive late-stage data. It would downgrade to bearish on any clinical delay, safety signal, or failure to secure non-dilutive funding. The next 12 months will be dictated almost entirely by clinical catalysts, with the base case of volatile range-trading being the most probable outcome as the story develops.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alumis Inc. Common Stock's 12-month outlook, with a consensus price target around $38.05 and implied upside of +30.0% versus the current price.
Average Target
$38.05
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$23 - $38
Analyst target range
The stock is covered by 7 analysts, and recent institutional ratings from firms like Morgan Stanley, HC Wainwright, and Wells Fargo uniformly show 'Buy' or 'Overweight' actions, indicating strong bullish sentiment. While a consensus price target is not explicitly provided in the data, the sustained 'Buy' ratings from multiple reputable firms following recent clinical updates and the stock's massive run-up suggest analysts see further upside, contingent on successful trial data. The target price range is not specified in the data, but the high level of institutional interest and the recent news of an $8 million purchase by Cormorant Asset Management signal confidence in the late-stage pipeline; conversely, the wide potential dispersion in targets would reflect the binary risk inherent in clinical-stage biotech, where the low target would assume clinical failure or significant delays. The pattern of recent ratings shows no downgrades, only reaffirmations of positive ratings, which typically reinforces bullish sentiment but also increases vulnerability to any negative clinical catalyst.
Bulls vs Bears: ALMS Investment Factors
The bull case, driven by explosive momentum, strong institutional backing, and transformative growth potential, is currently challenged by an unsustainable valuation and severe near-term cash burn. The bear side presents stronger evidence on a risk-adjusted basis, as the astronomical 345x PS ratio and complete lack of profits create an asymmetric downside risk profile. The single most important tension in the investment debate is whether upcoming late-stage clinical data will justify the market's sky-high growth expectations priced into the stock today. The resolution of this binary catalyst will determine if the stock resumes its ascent or faces a precipitous decline toward its fundamental value.
Bullish
- Strong Institutional Conviction: Recent news of a major investor's $8 million purchase and unanimous 'Buy' ratings from 7 analysts indicate deep conviction in the late-stage pipeline. This institutional backing, following a 400% stock surge, suggests sophisticated capital sees significant upside despite the run-up.
- Robust Balance Sheet & Low Leverage: The company maintains a strong current ratio of 4.34 and a low debt-to-equity ratio of 0.12, providing ample liquidity and financial flexibility to fund its clinical programs. This reduces near-term financing risk and operational stress.
- Explosive Price Momentum & Relative Strength: The stock has demonstrated extraordinary momentum with a 258.33% 1-year return and a 104.55% 3-month gain, significantly outperforming the SPY by 245.36% and 111.87% over those periods. This suggests powerful market recognition of the company's potential.
- Significant Analyst Revenue Growth Forecast: Analysts forecast average revenue of $840.35 million for the coming year, representing a massive leap from the current minimal $1.93 million quarterly run-rate. This growth expectation is the core driver of the current valuation and reflects high confidence in clinical success and commercialization.
Bearish
- Extreme Valuation Multiples: The stock trades at a staggering Price-to-Sales (PS) ratio of 345x, pricing in near-perfect execution and blockbuster sales. This leaves zero margin for error; any clinical setback or commercial delay would likely trigger a severe multiple contraction.
- Massive Cash Burn & No Profitability: The company is deeply unprofitable, burning -$71.91 million in free cash flow in Q4 2025 and -$370.18 million over the TTM. With an operating margin of -43.83%, the path to profitability is long and dependent on dilutive future financing or successful commercialization years away.
- Recent Sharp Pullback & High Volatility: The stock has retreated -31.93% over the past month, underperforming the SPY by -24.06%, indicating profit-taking and heightened risk aversion. This high volatility, with a 1-year max drawdown of -72.19%, underscores its event-driven, binary nature.
- Binary Clinical & Regulatory Risk: The entire $8.3 billion market cap is predicated on clinical trial success. The company has minimal revenue ($1.93M last quarter) and no commercial products. Negative late-stage data for envudeucitinib or A-005 could erase a majority of shareholder value.
ALMS Technical Analysis
The stock is in a powerful, sustained uptrend over the past year, evidenced by a staggering 258.33% 1-year price change. As of the latest close at $20.21, the price is trading approximately 66% of its 52-week range ($2.76 to $30.6), indicating it has retreated significantly from recent highs but remains well above its lows, suggesting a potential consolidation phase after a parabolic move. Recent momentum shows a sharp divergence, with a 1-month decline of -31.93% contrasting sharply with the 3-month gain of 104.55%, signaling a significant short-term pullback that may represent profit-taking or a reassessment of risk following the explosive rally. Key technical levels are clear, with immediate support at the 52-week low of $2.76 and formidable resistance at the 52-week high of $30.6; a decisive break above $30.6 would signal a resumption of the bull trend, while a sustained move below the recent low of $20.21 could indicate a deeper correction. The stock exhibits extreme volatility, with a 1-month relative strength of -24.06 against the SPY's -7.87% move, highlighting its high-beta, event-driven nature typical of clinical-stage biotechs.
Beta
-0.71
-0.71x market volatility
Max Drawdown
-36.7%
Largest decline past year
52-Week Range
$3-$31
Price range past year
Annual Return
+784.3%
Cumulative gain past year
| Period | ALMS Return | S&P 500 |
|---|---|---|
| 1m | +53.6% | +1.4% |
| 3m | +28.9% | +10.6% |
| 6m | +61.0% | +8.4% |
| 1y | +784.3% | +20.5% |
| ytd | +226.9% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALMS Fundamental Analysis
Revenue is minimal and highly variable, with the latest Q4 2025 figure at $1.93 million from collaboration, representing a sequential decline from Q3's $2.07 million but a significant improvement from $0 revenue in Q4 2024; this nominal revenue stream is not indicative of commercial traction, as the company remains entirely dependent on clinical trial outcomes for future growth. The company is deeply unprofitable, with a Q4 2025 net income of -$92.93 million and a gross margin of 55.05%, though the latter is distorted by low collaboration revenue; operating losses are substantial, with an operating margin of -43.83% for the quarter, reflecting heavy investment in R&D which totaled $76.52 million in Q4 alone. The balance sheet shows a strong current ratio of 4.34 and a low debt-to-equity ratio of 0.12, indicating good liquidity and low leverage, but cash flow is deeply negative with free cash flow of -$71.91 million in Q4 and a trailing twelve-month FCF of -$370.18 million, underscoring the company's complete reliance on external financing to fund its extensive clinical development pipeline.
Quarterly Revenue
$1929000.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
+0.55%
Latest Quarter
Free Cash Flow
$-370176000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALMS Overvalued?
Given the company's consistent net losses (Q4 2025 Net Income: -$92.93M), the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is an extraordinarily high 345.07x, while the forward-looking metric is not directly available, but analyst revenue estimates for the coming year average $840.35 million, which would imply a significant compression in the multiple if achieved, highlighting the market's extreme growth expectations priced into the current $8.3 billion market cap. Peer comparison is challenging due to the lack of industry average multiples in the provided data, but the astronomical PS ratio of 345x is indicative of a valuation that prices in near-perfect clinical success and blockbuster commercial potential, far exceeding typical biotech premiums. Historically, the stock's own PS ratio has fluctuated wildly, from 0 in 2024 to 529.78x at the end of Q4 2025; the current 345x, while down from its recent peak, remains near the top of its own historical band, suggesting the market is still pricing in highly optimistic scenarios despite the recent price pullback.
PE
-4.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -5x~1x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-33.2x
Enterprise Value Multiple
Investment Risk Disclosure
Paragraph 1 — Financial & Operational Risks: Alumis faces extreme financial risk from its massive cash burn, with a trailing twelve-month free cash flow of -$370.18 million and a Q4 2025 net loss of -$92.93 million. The company's operating margin of -43.83% indicates it is spending heavily on R&D ($76.52 million in Q4 alone) with no near-term path to profitability, creating total dependence on external financing. Revenue is minimal and erratic ($1.93M in Q4 2025 vs. $0 a year prior), offering no cushion against clinical delays, and the entire valuation is predicated on future success with zero current earnings power.
Paragraph 2 — Market & Competitive Risks: The stock's primary market risk is extreme valuation compression. Trading at a PS ratio of 345x, it is priced for flawless execution; any disappointment could trigger a rapid de-rating toward sector norms. The stock exhibits high-beta, event-driven volatility, underperforming the SPY by -24.06% in the last month, indicating it is highly sensitive to sentiment shifts and clinical news. Competitive risks are significant, as the autoimmune and neurology spaces are crowded with well-funded incumbents, and Alumis's success hinges on its TYK2 inhibitors demonstrating superior efficacy and safety in late-stage trials.
Paragraph 3 — Worst-Case Scenario: The worst-case scenario involves a clinical failure or significant safety setback for lead candidate envudeucitinib in its pivotal trials. This would likely collapse investor confidence, leading to analyst downgrades, institutional selling, and a rapid repricing of the stock toward its cash value or pre-catalyst levels. Given the 52-week low of $2.76 and a recent peak of $30.6, a realistic downside in this adverse scenario could be a -65% to -90% decline from the current $20.21 price, potentially revisiting the single-digit range as the market cap realigns with the company's remaining cash and early-stage pipeline value.
FAQ
The key risks are: 1) Clinical & Regulatory Risk (Highest Severity): The entire investment thesis hinges on positive late-stage trial results; failure could erase most of the stock's value. 2) Financial Risk: The company burns cash rapidly (-$71.9M FCF in Q4) and will need dilutive financing, threatening shareholder equity. 3) Valuation Risk: The 345x PS ratio leaves no margin for error; any disappointment will cause severe multiple compression. 4) Competitive & Market Risk: The autoimmune space is crowded, and the stock's high volatility (underperforming SPY by -24% last month) makes it sensitive to broad market sentiment and biotech sector rotations.
The 12-month forecast is highly bifurcated, with three scenarios: Bull Case (25% probability, target $30.6-$40) assumes flawless clinical success. Base Case (50% probability, target $15-$25) assumes volatile consolidation as the story develops, with valuation compressing from extreme levels. Bear Case (25% probability, target $2.76-$10) assumes a clinical setback leading to a collapse toward cash value. The base case is most likely, given the stock's recent 32% pullback from highs suggests the market is pricing in some risk, but the extreme valuation and binary catalysts make any forecast highly uncertain. The key assumption is the outcome of upcoming Phase 3 data.
ALMS is severely overvalued based on traditional financial metrics. It trades at a Price-to-Sales (PS) ratio of 345x, which is astronomical and prices in flawless clinical success and blockbuster future sales. The company is deeply unprofitable, with a net margin of -10.12% and negative earnings per share. The valuation is not grounded in current operations but in speculative future revenue, with analysts forecasting $840.35 million for the coming year. Compared to its own historical PS band (0 to 530x), the current 345x is near the peak, indicating the market is paying a massive premium for hope.
ALMS is a speculative buy only for investors with a very high risk tolerance and a long-term investment horizon. The stock has immense upside potential if its lead drug candidates succeed, as reflected in its 258% 1-year gain and unanimous analyst 'Buy' ratings. However, at a current Price-to-Sales ratio of 345x, it is extremely overvalued on any fundamental basis, and a clinical failure could lead to catastrophic losses, as seen in its -72% maximum drawdown. It is not suitable for conservative portfolios or short-term traders due to its binary, event-driven nature.
ALMS is suitable only for long-term investors with a 3-5 year horizon who can withstand extreme volatility and are investing based on the fundamental clinical and commercial potential of the pipeline. The stock's high beta and event-driven nature, evidenced by its 258% 1-year gain and -32% 1-month drop, make it a poor candidate for short-term trading. There is no dividend, and earnings visibility is zero until pivotal trial results are known and potential approval is secured. A minimum holding period should extend beyond the next major clinical catalyst, but investors must be prepared for significant price swings and potential dilution along the way.